Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated

Building Your Understanding of Hypermobility Syndrome (hEDS and HSD)

At a Glance

hEDS and HSD are related conditions involving flexible joints. hEDS requires generalized hypermobility, certain body-wide features or family history, and exclusion of other causes; HSD causes symptoms from hypermobility without meeting every hEDS requirement.

For many people living with hypermobility, the path to a name for their symptoms is often long and exhausting. You may have spent years being told your pain is “growing pains,” that you are simply “double-jointed,” or that your symptoms are all in your head [1][2]. In 2017, the medical community updated the way these conditions are classified to provide more clarity, yet many patients still find themselves caught between different labels like hEDS and HSD [3].

Understanding these conditions starts with recognizing that your symptoms are real, even if they don’t always fit into a single box. Whether you meet the strict criteria for a specific syndrome or fall elsewhere on the spectrum, the impact on your life and the need for support remain the same.

The 2017 Framework: hEDS vs. HSD

In 2017, international experts established new, stricter criteria to distinguish between different types of hypermobility [2]. It is helpful to think of these as points on a single spectrum of connective tissue health rather than entirely separate diseases.

Hypermobile Ehlers-Danlos Syndrome (hEDS)

To be diagnosed with hEDS, you must meet three specific “criteria” simultaneously [3]:

  1. Generalized Joint Hypermobility (GJH): This is measured using the Beighton Score, a 9-point system checking the flexibility of your pinky fingers, thumbs, elbows, knees, and spine [4]. The cutoff for “generalized” hypermobility changes with age; for example, children usually need a 6/9, while adults may only need a 5/9 or 4/9 [4][5].
  2. Systemic Features and Family History: You must show signs that your connective tissue is affected elsewhere, such as unusually soft or mildly stretchy skin, unexplained stretch marks, certain types of hernias, or a first-degree relative who also meets these criteria [2][6].
  3. Exclusion of Other Conditions: Your doctor must rule out other types of EDS (which often have known genetic markers) and other autoimmune or inflammatory conditions that can cause joint pain [7][8].

Hypermobility Spectrum Disorders (HSD)

If you have symptomatic joint hypermobility—meaning your joints are flexible and it is causing you pain or instability—but you do not meet all the strict systemic “check-boxes” for hEDS, you may be diagnosed with HSD [2].

It is a common misconception that HSD is a “milder” version of hEDS. Research shows that people with HSD can experience the same levels of chronic pain, fatigue, and disability as those with hEDS [9]. The difference is primarily in which diagnostic boxes are checked, not in the severity of the person’s daily struggle.

The Biology of Hypermobility

Unlike other types of Ehlers-Danlos syndrome, there is currently no single “universal gene” that identifies everyone with hEDS or HSD [10]. Instead, the condition is considered multifactorial, meaning it likely results from a combination of different genetic variations and environmental factors [11].

While it is hypothesized that the core issue may lie in the extracellular matrix (ECM)—the complex “scaffolding” that holds your cells together—this remains a research observation rather than a confirmed diagnostic model [12]. Some studies of skin cells from patients suggest that proteins meant to keep tissues strong—like collagen, fibronectin, and tenascin—may be disorganized [13][14]. It is important to remember that hEDS and HSD do not generally produce the marked organ fragility associated with rarer EDS subtypes, like Vascular EDS [4].

Beyond the Joints: A Multisystem Condition

Because connective tissue is found throughout your entire body, clinical overlaps can appear in many different systems [8]. Keep in mind these are associations, and alternative causes should always be considered:

  • Pain and Nerve Sensitivities: Some patients experience central sensitization, where the nervous system becomes “wound up” and over-responsive to pain signals [15]. Some studies also report emerging evidence of small-fiber neuropathy (damage to the tiny nerve endings in the skin), which may coexist and cause burning pain or tingling, though it requires proper evaluation [16][17].
  • The Autonomic Nervous System: It is common for some patients to experience dysautonomia, where the system that controls “automatic” functions like heart rate and blood pressure doesn’t work perfectly [18]. This may present as POTS (Postural Orthostatic Tachycardia Syndrome), causing dizziness, fainting, or a racing heart when you stand up [17].
  • Proprioception: Many people with hEDS/HSD have impaired proprioception—your body’s “internal GPS” that tells you where your limbs are in space [15]. This can make you feel clumsy or lead to more frequent joint injuries.

Why Diagnosis Can Be Difficult

Getting a clear diagnosis is often a challenge for several reasons:

  • Historical Terminology: Older terms like “Joint Hypermobility Syndrome” or “EDS-Hypermobility Type” were used for decades. Many doctors are still catching up to the 2017 updates [19][1].
  • Stricter Criteria: Since the 2017 criteria are much tougher, some people who were previously told they had hEDS may now technically fall into the HSD category [1].
  • The “Invisible” Nature: Because many of the systemic signs aren’t visible on a standard X-ray or blood test, symptoms are often dismissed until a specialist looks at the whole picture [8][2].

If you are navigating this journey, remember that your symptoms deserve management and validation regardless of which specific acronym—hEDS or HSD—is currently in your medical record. The goal of treatment remains focused on stabilizing joints, managing pain, and improving your quality of life.

Common questions in this guide

What is the difference between hEDS and HSD?
hEDS is diagnosed when a person meets all three parts of the 2017 criteria: generalized joint hypermobility, certain body-wide features or family history, and exclusion of other conditions. HSD is used when joint hypermobility causes symptoms but the person does not meet every hEDS criterion. The labels describe diagnostic criteria and do not determine how severe symptoms are.
Can HSD cause symptoms as severe as hEDS?
Yes. People with HSD can have levels of pain, fatigue, and disability similar to people with hEDS. HSD should not automatically be considered a mild form of hEDS.
How is hEDS diagnosed?
A clinician assesses generalized joint hypermobility with the nine-point Beighton Score, checks for certain connective-tissue features or a relevant first-degree family history, and rules out other conditions that can cause similar symptoms. The Beighton cutoff varies with age, and prior injuries may affect the assessment. There is currently no single genetic test that identifies everyone with hEDS.
What does a Beighton score mean?
The Beighton Score is a nine-point examination of flexibility in the pinky fingers, thumbs, elbows, knees, and spine. Higher scores indicate more generalized joint hypermobility, but the cutoff used can depend on age. A score alone does not diagnose hEDS or HSD.
Is there a genetic test for hEDS or HSD?
There is no single universal gene or genetic test that identifies everyone with hEDS or HSD. A clinician may still consider genetic testing when another connective-tissue disorder is possible, especially because some other Ehlers-Danlos types have known genetic markers. Test decisions depend on the person's findings and family history.
What symptoms can occur beyond flexible joints?
Some people report chronic pain, fatigue, dizziness or fainting when standing, a racing heart, burning or tingling sensations, digestive symptoms, or problems sensing where their limbs are in space. These can be associated with conditions such as dysautonomia, POTS, central sensitization, or small-fiber neuropathy, but they can have other causes. A clinician should evaluate symptoms rather than assuming they are all due to hypermobility.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on hypermobility syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which of the 2017 diagnostic criteria for hEDS do I meet, and which ones do I not?
  2. 2.If I meet the criteria for Hypermobility Spectrum Disorder (HSD) instead of hEDS, how does that change my management plan or the validation of my symptoms?
  3. 3.What was my Beighton score during the exam, and how did you account for my age and any prior injuries?
  4. 4.Based on my symptoms, are there any other connective tissue disorders we need to rule out through genetic testing or other imaging?
  5. 5.Can you help me understand how much of my pain is coming from joint instability versus other factors like central sensitization or small-fiber neuropathy?
  6. 6.Are you comfortable managing the systemic symptoms I’m experiencing (like fatigue or digestive issues), or should I be referred to other specialists familiar with hypermobility?

References

References (19)
  1. 1

    Utilization of the 2017 diagnostic criteria for hEDS by the Toronto GoodHope Ehlers-Danlos syndrome clinic: A retrospective review.

    McGillis L, Mittal N, Santa Mina D, et al.

    American journal of medical genetics. Part A 2020; (182(3)):484-492 doi:10.1002/ajmg.a.61459.

    PMID: 31840928
  2. 2

    Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.

    Yew KS, Kamps-Schmitt KA, Borge R

    American family physician 2021; (103(8)):481-492.

    PMID: 33856167
  3. 3

    Prevalence of hypermobile Ehlers-Danlos syndrome in postural orthostatic tachycardia syndrome.

    Miller AJ, Stiles LE, Sheehan T, et al.

    Autonomic neuroscience : basic & clinical 2020; (224()):102637 doi:10.1016/j.autneu.2020.102637.

    PMID: 31954224
  4. 4

    Pediatric joint hypermobility: a diagnostic framework and narrative review.

    Tofts LJ, Simmonds J, Schwartz SB, et al.

    Orphanet journal of rare diseases 2023; (18(1)):104 doi:10.1186/s13023-023-02717-2.

    PMID: 37143135
  5. 5

    Generalized Joint Hypermobility: A Statistical Analysis Identifies Non-Axial Involvement in Most Cases.

    Lamari MM, Lamari NM, de Medeiros MP, et al.

    Children (Basel, Switzerland) 2024; (11(3)) doi:10.3390/children11030344.

    PMID: 38539379
  6. 6

    Diagnosis and Management of Hypermobility Spectrum Disorders in Primary Care.

    Atwell K, Michael W, Dubey J, et al.

    Journal of the American Board of Family Medicine : JABFM 2021; (34(4)):838-848 doi:10.3122/jabfm.2021.04.200374.

    PMID: 34312277
  7. 7

    Differential diagnosis and diagnostic flow chart of joint hypermobility syndrome/ehlers-danlos syndrome hypermobility type compared to other heritable connective tissue disorders.

    Colombi M, Dordoni C, Chiarelli N, Ritelli M

    American journal of medical genetics. Part C, Seminars in medical genetics 2015; (169C(1)):6-22 doi:10.1002/ajmg.c.31429.

    PMID: 25821090
  8. 8

    Hypermobile Ehlers-Danlos Syndrome: Diagnostic Challenges and the Role of Genetic Testing.

    Forghani I, See J, McGonigle WC

    Genes 2025; (16(5)) doi:10.3390/genes16050530.

    PMID: 40428350
  9. 9

    Localized and historical hypermobile spectrum disorders share self-reported symptoms and comorbidities with hEDS and HSD.

    Fairweather D, Bruno KA, Darakjian AA, et al.

    Frontiers in medicine 2025; (12()):1594796 doi:10.3389/fmed.2025.1594796.

    PMID: 40880755
  10. 10

    Complex Genetics and Regulatory Drivers of Hypermobile Ehlers-Danlos Syndrome: Insights from Genome-Wide Association Study Meta-analysis.

    Petrucci-Nelson T, Guilhaumou S, Berrandou TE, et al.

    medRxiv : the preprint server for health sciences 2025; doi:10.1101/2025.09.19.25336146.

    PMID: 41001447
  11. 11

    KLK15 alters connective tissues in hypermobile Ehlers-Danlos syndrome.

    Gensemer C, Petrucci T, Beck T, et al.

    iScience 2025; (28(9)):113343 doi:10.1016/j.isci.2025.113343.

    PMID: 40949095
  12. 12

    Dermal fibroblast-to-myofibroblast transition sustained by αvß3 integrin-ILK-Snail1/Slug signaling is a common feature for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.

    Zoppi N, Chiarelli N, Binetti S, et al.

    Biochimica et biophysica acta. Molecular basis of disease 2018; (1864(4 Pt A)):1010-1023 doi:10.1016/j.bbadis.2018.01.005.

    PMID: 29309923
  13. 13

    RNA-Seq of Dermal Fibroblasts from Patients with Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders Supports Their Categorization as a Single Entity with Involvement of Extracellular Matrix Degrading and Proinflammatory Pathomechanisms.

    Ritelli M, Chiarelli N, Cinquina V, et al.

    Cells 2022; (11(24)) doi:10.3390/cells11244040.

    PMID: 36552803
  14. 14

    Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts.

    Zoppi N, Chiarelli N, Ritelli M, Colombi M

    International journal of molecular sciences 2018; (19(4)) doi:10.3390/ijms19040982.

    PMID: 29587413
  15. 15

    Hypermobility, the Ehlers-Danlos syndromes and chronic pain.

    Syx D, De Wandele I, Rombaut L, Malfait F

    Clinical and experimental rheumatology 2017; (35 Suppl 107(5)):116-122.

    PMID: 28967365
  16. 16

    Skin biopsy reveals generalized small fibre neuropathy in hypermobile Ehlers-Danlos syndromes.

    Igharo D, Thiel JC, Rolke R, et al.

    European journal of neurology 2023; (30(3)):719-728 doi:10.1111/ene.15649.

    PMID: 36437696
  17. 17

    Hypermobile Ehlers-Danlos Syndrome: Cerebrovascular, Autonomic and Neuropathic Features.

    Novak P, Systrom DM, Marciano SP, et al.

    American journal of medicine open 2025; (14()):100111 doi:10.1016/j.ajmo.2025.100111.

    PMID: 40843452
  18. 18

    A new insight on postural tachycardia syndrome in 102 adults with hypermobile Ehlers-Danlos Syndrome/hypermobility spectrum disorder.

    Celletti C, Borsellino B, Castori M, et al.

    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2020; (90(2)) doi:10.4081/monaldi.2020.1286.

    PMID: 32434316
  19. 19

    Joint Hypermobility Syndrome: Recognizing a Commonly Overlooked Cause of Chronic Pain.

    Kumar B, Lenert P

    The American journal of medicine 2017; (130(6)):640-647 doi:10.1016/j.amjmed.2017.02.013.

    PMID: 28286166

This page explains hEDS and HSD for informational purposes only and does not constitute medical advice or diagnose your condition. Discuss your symptoms, examination findings, and care plan with a qualified healthcare professional.